[go: up one dir, main page]

BR9206073A - Derivados de quinuclidina - Google Patents

Derivados de quinuclidina

Info

Publication number
BR9206073A
BR9206073A BR9206073A BR9206073A BR9206073A BR 9206073 A BR9206073 A BR 9206073A BR 9206073 A BR9206073 A BR 9206073A BR 9206073 A BR9206073 A BR 9206073A BR 9206073 A BR9206073 A BR 9206073A
Authority
BR
Brazil
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
Prior art date
Application number
BR9206073A
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
Lowe John Adams Iii
Terry Jay Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9206073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR9206073A publication Critical patent/BR9206073A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9206073A 1991-05-31 1992-04-28 Derivados de quinuclidina BR9206073A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (en) 1991-05-31 1992-04-28 bibNUCLIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
BR9206073A true BR9206073A (pt) 1994-12-06

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9206073A BR9206073A (pt) 1991-05-31 1992-04-28 Derivados de quinuclidina

Country Status (41)

Country Link
US (3) US5807867A (pt)
EP (1) EP0587723B1 (pt)
JP (2) JPH0733386B2 (pt)
KR (1) KR100214905B1 (pt)
CN (1) CN1048492C (pt)
AP (1) AP299A (pt)
AT (1) ATE135006T1 (pt)
AU (1) AU657552B2 (pt)
BG (1) BG61694B1 (pt)
BR (1) BR9206073A (pt)
CA (1) CA2102179C (pt)
CZ (1) CZ281403B6 (pt)
DE (4) DE122006000066I1 (pt)
DK (1) DK0587723T3 (pt)
EG (1) EG19944A (pt)
ES (1) ES2084361T3 (pt)
FI (1) FI114475B (pt)
GR (1) GR3019687T3 (pt)
GT (1) GT199200028A (pt)
HU (1) HU217548B (pt)
IE (1) IE72473B1 (pt)
IL (1) IL102008A (pt)
IS (1) IS1611B (pt)
LU (1) LU91293I2 (pt)
MA (1) MA22539A1 (pt)
MX (1) MX9202554A (pt)
NL (1) NL300250I2 (pt)
NO (2) NO302701B1 (pt)
NZ (2) NZ242956A (pt)
OA (1) OA09867A (pt)
PL (1) PL171379B1 (pt)
PT (1) PT100546B (pt)
RO (1) RO110499B1 (pt)
RU (1) RU2103269C1 (pt)
SK (1) SK390692A3 (pt)
TW (1) TW204349B (pt)
UA (1) UA27776C2 (pt)
UY (1) UY23422A1 (pt)
WO (1) WO1992021677A1 (pt)
YU (1) YU48995B (pt)
ZA (1) ZA923942B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733386B2 (ja) * 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
AU4224993A (en) * 1992-08-19 1994-03-15 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
AU676489B2 (en) * 1992-11-12 1997-03-13 Pfizer Inc. Quinuclidine derivative as substance P antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
BR9908895A (pt) * 1998-03-19 2000-12-05 Takeda Chemical Industries Ltd Composição farmacêutica, composto, pró-medicamento, composições para antagonizar um receptor, uso de um composto, e, processos para produzir um composto, para antagonizar um receptor, para evitar ou tratar distúrbios de micção em mamìferos e distúrbios de asma, artrite reumatóide, osteoartrite, dor, tosse, sìndrome do intestino irritável ou vÈmitos em mamìferos
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
WO2002004455A2 (en) 2000-07-11 2002-01-17 Albany Molecular Research, Inc 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
KR20040029375A (ko) * 2001-07-20 2004-04-06 화이자 프로덕츠 인코포레이티드 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한nk-1 수용체 길항제의 용도
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
PT1592384E (pt) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
US20050136487A1 (en) * 2003-10-27 2005-06-23 Meyer Donald W. Transmissible spongiform encephalopathy detection in cervids, sheep and goats
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
RU2332997C2 (ru) * 2004-01-30 2008-09-10 Пфайзер Продактс Инк. АНТИМИКРОБНЫЕ КОНСЕРВАНТЫ ДЛЯ ДОСТИЖЕНИЯ МУЛЬТИДОЗОВЫХ РЕЦЕПТУР С ИСПОЛЬЗОВАНИЕМ β-ЦИКЛОДЕКСТРИНОВ ДЛЯ ЖИДКИХ ЛЕКАРСТВЕННЫХ ФОРМ
JP2007519701A (ja) * 2004-01-30 2007-07-19 ファイザー・プロダクツ・インク 麻酔回復を改善するためのnk−1受容体拮抗剤
RU2320659C9 (ru) * 2004-02-02 2008-07-20 Пфайзер Продактс Инк. Способы получения 1-(2s, 3s)-2-бензгидрил-n-(5-трет-бутил-2-метоксибензил)хинуклидин-3-амина в виде камфорсульфатной соли, цитратной соли и свободного основания и промежуточное соединение
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ, インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5451586A (en) * 1990-06-01 1995-09-19 Pfizer Inc. 3-amino-2-aryl quinuclidines
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
JPH0733386B2 (ja) * 1991-05-31 1995-04-12 フアイザー・インコーポレイテツド キヌクリジン誘導体
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DE59605542D1 (de) * 1996-01-19 2000-08-10 Lonza Ag Verfahren zur Herstellung von optisch aktivem 3-Chinuclidinol
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
JPH07285965A (ja) 1995-10-31
YU48995B (sh) 2003-04-30
NL300250I2 (nl) 2007-03-01
DE69208877D1 (de) 1996-04-11
FI935297L (fi) 1993-11-29
GT199200028A (es) 1993-11-20
NO2007003I1 (no) 2007-03-26
IL102008A0 (en) 1992-12-30
MA22539A1 (fr) 1992-12-31
AU1990192A (en) 1993-01-08
DK0587723T3 (da) 1996-04-01
CN1048492C (zh) 2000-01-19
JPH06504292A (ja) 1994-05-19
MX9202554A (es) 1992-11-01
BG98248A (bg) 1994-07-29
CZ390692A3 (en) 1994-02-16
CZ281403B6 (cs) 1996-09-11
US5807867A (en) 1998-09-15
HU217548B (hu) 2000-02-28
KR100214905B1 (ko) 1999-08-02
BG61694B1 (bg) 1998-03-31
DE9290063U1 (de) 1994-02-24
NO934312L (no) 1993-11-29
SK278788B6 (sk) 1998-02-04
RU2103269C1 (ru) 1998-01-27
YU56492A (sh) 1995-03-27
NO2007003I2 (no) 2011-04-18
NZ242956A (en) 1995-06-27
PT100546A (pt) 1993-08-31
IE921729A1 (en) 1992-12-02
HU9303393D0 (en) 1994-03-28
HUT70151A (en) 1995-09-28
AU657552B2 (en) 1995-03-16
AP299A (en) 1994-01-14
CA2102179C (en) 1998-10-27
CA2102179A1 (en) 1992-12-01
NO302701B1 (no) 1998-04-14
FI114475B (fi) 2004-10-29
AP9200384A0 (en) 1992-07-31
CN1067428A (zh) 1992-12-30
EG19944A (en) 1997-02-27
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
US6222038B1 (en) 2001-04-24
NO934312D0 (no) 1993-11-29
IS3871A (is) 1992-12-02
UY23422A1 (es) 1992-11-12
ATE135006T1 (de) 1996-03-15
EP0587723B1 (en) 1996-03-06
PT100546B (pt) 1999-12-31
UA27776C2 (uk) 2000-10-16
JPH0733386B2 (ja) 1995-04-12
IS1611B (is) 1996-10-18
RO110499B1 (ro) 1996-01-30
IE72473B1 (en) 1997-04-23
TW204349B (pt) 1993-04-21
DE69208877T2 (de) 1996-07-25
NZ270673A (en) 1997-07-27
NL300250I1 (nl) 2007-02-01
SK390692A3 (en) 1998-02-04
DE122006000066I2 (de) 2007-12-06
WO1992021677A1 (en) 1992-12-10
FI935297A0 (fi) 1993-11-29
US5939433A (en) 1999-08-17
PL171379B1 (en) 1997-04-30
JP2645225B2 (ja) 1997-08-25
ZA923942B (en) 1993-11-29
EP0587723A1 (en) 1994-03-23
IL102008A (en) 1995-12-08
DE122006000066I1 (de) 2007-03-22
ES2084361T3 (es) 1996-05-01
GR3019687T3 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
PT100546A (pt) Derivados de quinuclidina
FI924160A7 (fi) Benzanilidderivat
FI935726A7 (fi) Atsanorbornaanijohdannaisia
FI924159L (fi) Benzanilidderivat
NO922182D0 (no) Krystallinske oksatiolan-derivater
FI925422L (fi) Indolopyrrolokarbazolderivat
FI921262L (fi) 4-aryltiazol- eller 4-arylimidazolderivat
NO924890L (no) Imidazopyridiner
FI923726L (fi) Sulfaterade glykosaminoglykanoidderivat
FI925763L (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
FI930345L (fi) Foerfarande foer framstaellning av renat akrylamidosulfonsyramonomerderivat
FI935243L (fi) Pyridonkarboxylsyraderivat
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
FI925314A7 (fi) Cefalosporinderivat
DE69222599D1 (de) Cephalosporin-Derivate
DE59207540D1 (de) Resolver
FI920394A7 (fi) 3-kinuklidiinijohdannaiset
MX9206710A (es) Derivados de piridinol
FI924145L (fi) 3-cykloalkylprop-2-enamidderivat
FI921597A7 (fi) Maetning av en hisskorgs position med hjaelp av ultraljud
FI942070A7 (fi) Nitroksialkyyliamidijohdannaiset
FI935293A7 (fi) Propensyraderivat
FI933346A7 (fi) Aminoalkylpyrrolidinyltiokarbapenemderivat
BR9104543A (pt) Derivados de triazolpiridazina
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal
B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.004403/05 38A VARA FEDERAL DO RIO DE JANEIRO PROC. NO 2005.51.01.522482-6 ACAO DE PROCEDIMENTO ORDINARIO/PROPRIEDADE INDUSTRIAL AUTOR: PFIZER INC. REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REQUER: REVISAO DA DECISAO ADMINISTRATIVA DO INPI QUE INDEFERIU O PEDIDO DE PATENTE.